[proxy] pubmed.ncbi.nlm.nih.gov — ← back | site home | direct (HTTPS) ↗ | proxy home | ◑ dark◐ light

Risk of seizures in transcranial magnetic stimulation: a clinical review to inform consent process focused on bupropion - PubMed

Christine E Dobek  1 ,

Review

. 2015 Nov 30:11:2975-87.

doi: 10.2147/NDT.S91126. eCollection 2015.

Affiliations

Review

Risk of seizures in transcranial magnetic stimulation: a clinical review to inform consent process focused on bupropion

Christine E Dobek et al. Neuropsychiatr Dis Treat. .

Abstract

Objective: When considering repetitive transcranial magnetic stimulation (rTMS) for major depressive disorder, clinicians often face a lack of detailed information on potential interactions between rTMS and pharmacotherapy. This is particularly relevant to patients receiving bupropion, a commonly prescribed antidepressant with lower risk of sexual side effects or weight increase, which has been associated with increased risk of seizure in particular populations. Our aim was to systematically review the information on seizures occurred with rTMS to identify the potential risk factors with attention to concurrent medications, particularly bupropion.

Data sources: We conducted a systematic review through the databases PubMed, PsycINFO, and EMBASE between 1980 and June 2015. Additional articles were found using reference lists of relevant articles. Reporting of data follows Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.

Study selection: Two reviewers independently screened articles reporting the occurrence of seizures during rTMS. Articles reporting seizures in epilepsy during rTMS were excluded. A total of 25 rTMS-induced seizures were included in the final review.

Data extraction: Data were systematically extracted, and the authors of the applicable studies were contacted when appropriate to provide more detail about the seizure incidents.

Results: Twenty-five seizures were identified. Potential risk factors emerged such as sleep deprivation, polypharmacy, and neurological insult. High-frequency-rTMS was involved in a percentage of the seizures. None of these seizures reported had patients taking bupropion in the literature review. One rTMS-induced seizure was reported from the Food and Drug Administration in a sleep-deprived patient who was concurrently taking bupropion, sertraline, and amphetamine.

Conclusion: During the consent process, potential risk factors for an rTMS-induced seizure should be carefully screened for and discussed. Data do not support considering concurrent bupropion treatment as contraindication to undergo rTMS.

Keywords: bupropion; consent process; interaction; repetitive transcranial magnetic stimulation; seizures.

PubMed Disclaimer

Figures

Figure 1

Patients with an rTMS-induced seizure categorized by area of cortex stimulated (cortex), sex, type of TMS administered, and possible risk factors. Abbreviations: rTMS, repetitive transcranial magnetic stimulation; TMS, transcranial magnetic stimulation; HF, high frequency; LF, low frequency; SP, single pulse; TBS, theta-burst stimulation; MC, preexisting medical condition; Meds, medications; Sleep, sleep deprived; Sz Hx, history of seizures; Alcohol, influence of alcohol.

Figure 2

The number and combination of medications that each of the patients (n=25) was taking during the time of accidental rTMS-induced seizure: including no medication (none, n=4, 16%), one medication (n=4, 16%), two medications (n=3, 12%), three medications or more (n=3, 12%), and medications not reported (n=11, 44%). Abbreviation: rTMS, repetitive transcranial magnetic stimulation.

References

    1. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group P referred R eporting I tems for S ystematic Reviews and M eta-A nalyses: The PRISMA Statement. PLoS Med. 2009;6(6):e1000097. doi: 10.1371/journal.pmed1000097. - DOI - PMC - PubMed
    1. Kennedy SH, Milev R, Giacobbe P, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies. J Affect Disord. 2009;117:S44–S53. - PubMed
    1. Jhanwar VG, Bishnoi RJ, Jhanwar MR. Utility of repetitive transcranial stimulation as an augmenting treatment method in treatment-resistant depression. Indian J Psychol Med. 2011;33(1):92–96. - PMC - PubMed
    1. Rossi S, Hallett M, Rossini PM, Pascual-Leone A. Safety of TMS Consensus Group. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol. 2009;120:2008. - PMC - PubMed
    1. Tripp AC. Bupropion, a brief history of seizure risk. Gen Hosp Psychiatry. 2010;32(2):216–217. - PubMed